Want to see PETV full AI Analyst Report?
PETV Stock Chart & Stats
$0.64
<$0.01(1.20%)
At close: 4:00 PM EDT
$0.64
<$0.01(1.20%)
Day’s Range― - ―
52-Week Range$0.59 - $1.69
Previous CloseN/A
Volume3.52K
Average Volume (3M)15.87K
Market Cap
$26.57M
Enterprise Value$31.52M
Total Cash (Recent Filing)$122.63K
Total Debt (Recent Filing)$515.11K
Price to Earnings (P/E)―
Beta0.19
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding37,950,497
10 Day Avg. Volume23,431
30 Day Avg. Volume15,870
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)9.60
Price to Sales (P/S)18.49
P/FCF Ratio-3.45
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue26.67
Enterprise Value/Gross Profit39.83
Enterprise Value/Ebitda-3.81
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High-margin Spryng GrowthThe shift toward Spryng supports a more attractive product mix, with substantially higher margins than the company’s overall reported level. If adoption continues through veterinary channels, this mix improvement could strengthen gross profit and create better operating leverage over the next several quarters.
Regulatory And Clinical ValidationHealth Canada recognition creates a pathway for international commercialization and provides external validation of Spryng’s regulatory positioning. Continued peer-reviewed evidence and canine or equine studies can support veterinarian confidence, market access, and durable adoption of the platform.
AI Commercial OpportunityPetVivo.ai could broaden the company beyond product sales by adding a recurring revenue stream with projected high gross margins. The reported reduction in customer acquisition costs and strong beta accuracy, if sustained commercially, may improve scalability and support more efficient veterinary-market expansion.
Bears Say
Persistent Losses And Cash BurnThe current revenue base remains far too small to cover operating costs, leaving the company dependent on continued funding while it pursues growth. Persistent losses and negative free cash flow can erode equity, constrain investment capacity, and make execution more vulnerable if commercialization takes longer than expected.
Tight Liquidity And Financing DependenceA very limited cash balance leaves little room to absorb operating volatility or fund planned clinical and commercial initiatives internally. Reliance on pending subscriptions and a larger capital raise creates financing and dilution risk, while delays could restrict growth plans or complicate the PBM transaction.
External Funding And Grant RelianceDependence on grants, tax credits, and outside capital makes important R&D and clinical programs contingent on funding outcomes beyond the company’s direct control. Unsuccessful or delayed awards could slow technology development, reduce commercialization momentum, and increase pressure on already limited internal liquidity.
PetVivo Holdings News
PETV FAQ
What was PetVivo Holdings’s price range in the past 12 months?
PetVivo Holdings lowest stock price was $0.59 and its highest was $1.69 in the past 12 months.
What is PetVivo Holdings’s market cap?
PetVivo Holdings’s market cap is $26.57M.
When is PetVivo Holdings’s upcoming earnings report date?
PetVivo Holdings’s upcoming earnings report date is Nov 18, 2026 which is in 25 days.
How were PetVivo Holdings’s earnings last quarter?
PetVivo Holdings released its earnings results on Aug 14, 2026. The company reported -$0.047 earnings per share for the quarter.
Is PetVivo Holdings overvalued?
According to Wall Street analysts PetVivo Holdings’s price is currently Overvalued.
Does PetVivo Holdings pay dividends?
PetVivo Holdings does not currently pay dividends.
What is PetVivo Holdings’s EPS estimate?
PetVivo Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PetVivo Holdings have?
PetVivo Holdings has 37,950,497 shares outstanding.
What happened to PetVivo Holdings’s price movement after its last earnings report?
PetVivo Holdings reported an EPS of -$0.047 in its last earnings report. Following the earnings report the stock price went up 0.294%.
Which hedge fund is a major shareholder of PetVivo Holdings?
Currently, no hedge funds are holding shares in PETV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PetVivo Holdings
PetVivo Holdings, Inc. operates as a biomedical technology firm, specializing in the invention, commercialization, and licensing of advanced medical devices and biomaterials intended to treat a variety of ailments and diseases affecting animals. Its flagship product is Spryng, an intra-articular injection administered by veterinarians to effectively alleviate lameness and joint conditions, such as osteoarthritis, in canines and equines. The company's development pipeline further includes seventeen therapeutic devices poised for both veterinary and human clinical applications. Founded in 2009, PetVivo Holdings, Inc. maintains its corporate headquarters in Minneapolis, Minnesota.
PETV Company Deck
PETV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call communicated meaningful commercial, product and technological progress — including double-digit revenue growth, margin improvement, international regulatory recognition, strong AI beta results, and strategic M&A and partnership activity. However, the company remains small in absolute revenue, continues to report operating and net losses, has a tight cash balance ($123k) and depends on pending financing and grants (including a referenced $5M raise to close the PBM acquisition). The positives around product validation, high-margin pipeline opportunities and operational improvements are balanced by liquidity, financing and execution risks.View all PETV earnings summariesTechnical Analysis
Ownership Overview
66.90% Insiders
0.34% Other Institutional Investors
32.77% Public Companies and
Individual Investors